Back

SNO 2019 - Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Nov 20 - Nov 24, 2019 | PhoenixAZUS

LARVOL is not affiliated with Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology and all trademarks, logos, and brand names are property of their respective owners

Top Trials
Top Trials has no data

Showing 120 abstracts linked to Trials

EXTH-27 - Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator GITRL

DDIS-03 - Development of a novel class of cGAS agonists to trigger STING pathway-dependent innate immune responses against Glioblastoma

ATIM-08 - Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-naïve, recurrent glioblastoma

  • E-Poster

INNV-10 - Safety of apixaban for venous thromboembolism prevention in patients with newly diagnosed glioblastoma

  • E-Poster

INNV-30 - Response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutated glioblastoma: a case report

  • E-Poster

PDCT-16 - A phase I study of Suberoylanilide Hydroxamic Acid (SAHA) with Temsirolimus in children with newly diagnosed or progressive diffuse intrinsic pontine glioma (DIPG)

  • E-Poster

ACTR-29 - A series of patients (pts) with recurrent GBM (rGBM) treated with ABT-414, bevacizumab (Bev) and CCNU

  • E-Poster

INNV-41 - Prospective selection of recurrent glioblastoma patients for tailored therapies. Results of an institutional experience.

  • E-Poster

PDTM-23 - Delta-24-RGD oncolytic adenovirus mediates anti-tumor effect in localized and disseminated AT/RT murine models

  • E-Poster

RARE-39 - Combination of Tumor Treating Fields (TTFields) with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis

  • E-Poster

ATIM-47 - Nivolumab vs bevacizumab in patients with recurrent glioblastoma: exploratory analysis of MGMT methylation status and baseline corticosteroid use